MedTrace Logo

Individualized Treatments in Adults With Relapsed/Refractory Cancers

NCT06024603 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-02-12

No results posted yet for this study

Summary

A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.

Conditions

  • Refractory Cancer
  • Relapsed Cancer

Interventions

DIAGNOSTIC_TEST

Drug Sensitivity Test (DST)

Refractory cancer tissue will be collected from participants and subjected to single-drug testing while DNA is simultaneously sent for targeted gene sequencing. Drug sensitivity scores from the tests will become available for a final list of therapeutic options ranked best in order of preference together with suggested doses and schedules.

Sponsors & Collaborators

  • Florida International University

    collaborator OTHER

  • Community Foundation of Broward

    collaborator UNKNOWN

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Jorge Manrique-Succar, MD · Lerner College of Medicine, Cleveland Clinic Florida

  • Diana Azzam, PhD · Robert Stempel College of Public Health and Social Work, Florida International University

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-20
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06024603 on ClinicalTrials.gov